Thursday, January 12, 2012
Pharmos Corp., of Iselin, N.J., said the first U.S. patients have been dosed with its levotofisopam (S-tofisopam) in a Phase IIa proof-of-concept trial in hyperuricemia and gout. In two Phase I studies, completed by Vela Pharmaceuticals, which merged with Pharmos in 2006, levotofisopam was generally well tolerated and was associated with a large, rapid reduction in serum uric acid values.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.